Catherine J. Lee, MD, MS, associate professor of medicine in the Clinical Research Division at Fred Hutchinson Cancer Center in Seattle, Washington, led a live virtual discussion on how to treat patients with chronic graft-vs-host disease (GVHD) and how best to assess the extent of their disease.
During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed with participants what therapy to use, including adjuvant immunotherapy, for a patient with stage III non–small cell lung cancer. This is the second of 2 articles based on this event.
Health-related quality of life measures from the phase 3 DESTINY-Breast03 trial showed that patient-reported outcomes and time of hospitalization data favored trastuzumab deruxtecan despite having a longer duration of treatment than trastuzumab emtansine.
During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed with oncologists how they use loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma.
In the second article of a 2-part series, Hans Hammers, MD, PhD, leads a discussion on the adverse events seen with the use of tyrosine kinase inhibitors in the treatment of patients with renal cell carcinoma.
During a Targeted Oncology™ Clinical Case Forum™ event, Ronan J. Kelly, MD, MBA, discussed the significance of the CheckMate 9LA, KEYNOTE-407, EMPOWER-Lung 3, and POSEIDON studies which all explored immunotherapies in patients with advanced non–small cell lung cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed when in sequence they would use sacituzumab govitecan for patients with metastatic urothelial cancer. This is the second of 2 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Nizar M. Tannir, MD, discussed with participants their experiences with the combination of lenvatinib and pembrolizumab, including the dosing schedule of pembrolizumab and finding a tolerable dose of lenvatinib.
During a Targeted Oncology™ Case-Based Roundtable™ event, Carol Ann Huff, MD, and other physicians discussed how they expect to use bispecific agents and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma as the field advances.
During a Targeted Oncology™ Case-Based Roundtable™ event, Hatem Soliman, MD, discussed how the FDA approval of elacestrant impacts the treatment setting of ER+, HER2- breast cancer
In the second article of a 2-part article series, Joshua Lang, MD, and live event participants discuss the role of cabazitaxel for the treatment of patients with prostate cancer who harbor certain mutations or have other factors that make their disease unique.
During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed the use of sotorasib and adagrasib in patients with KRAS G12C mutations in non–small cell lung cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, Ariel F. Grajales-Cruz, MD, discussed second-line therapy combinations for a patient with early-relapse multiple myeloma after complete remission with bortezomib, lenalidomide, and dexamethasone.
During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Campbell, MD, MS, discussed guidelines and available therapies for a patient who requires second-line treatment and beyond for metastatic renal cell carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed when they would use monotherapy or doublet therapy in metastatic melanoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, and participants discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab.
During a Targeted Oncology™ Case-Based Roundtable™ event, Chakra P. Chaulagain, MD, and participants discussed how they would treat a 54-year-old woman diagnosed with transplant-eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
In the second article of a 2-part series, Alfred Garfall, MD, discussed how to best treat patients with multiple myeloma after they undergo transplant and whether continuing quadruplet therapy can provide a benefit before maintenance therapy.
During a Targeted Oncology™ Case-Based Roundtable™ event, Danko Martincic, MD, outlined the definition, risk factors, and treatment for patients with tumor lysis syndrome.
During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed the use of elacestrant for patients who have received prior endocrine therapy for ER-positive, HER2-negative breast cancer. This is the second of 2 articles based on this event.
In an interview with Targeted Oncology, Arturo Loaiza-Bonilla, MD, MSEd, discussed the growing use of artificial intelligence in oncology practices. Loaiza-Bonilla is a medical oncologist and cofounder of Massive Bio, a company that uses AI to connect oncologists and patients with cancer to clinical trials of novel treatments.
During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, and participants discussed using immunotherapy plus tyrosine kinase inhibitor to treat advanced renal cell carcinoma. This is the second of 2 articles based on this event.
At a live, virtual Case-Based Roundtable meeting, Bradley McGregor, MD, discussed with fellow physicians how best to integrate new approaches to treatment for patients with relapsed or refractory clear cell renal cell carcinoma.
Ashwin Kishtagari, MD, discusses the PERSIST-2 trial of pacritinib for patients with primary myelofibrosis and low platelet counts.
In the first of a 2-part article series, Kartik Konduri, MD, discusses the data behind the use of adagrasib and sotorasib for patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.
During a Targeted Oncology™ Community Case Forum™ event, Hans Hammers, MD, discussed trials that shed light on the role of adjuvant therapies for patients with stage II and III renal cell carcinoma.
During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth A. Mittendorf, MD, PhD, discussed the TROPiCS-02 trial of sacituzumab govitecan for patients with hormone receptor–positive, HER2-negative breast cancer.
During a Targeted Oncology™ Case-Based Roundtable™ event, D. Ross Camidge, MD, PhD, discussed dosing and toxicity concerns with the KRAS inhibitors adagrasib and sotorasib.
During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed options including concurrent chemoradiation therapy and neoadjuvant therapy for a patient with stage IIIA lung adenocarcinoma.
In separate, live virtual events, Jonathan L. Kaufman, MD, and Morie A. Gertz, MD, MACP, discussed concerns about using chimeric antigen receptor T-cell therapy for a patient with relapsed/refractory multiple myeloma who is experiencing rapid disease progression.